1. Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537–545.
2. Flecknell P. Analgesia and post-operative care. In: Flecknell P, ed. Laboratory animal anaesthesia. 3rd ed. Amsterdam: Elsevier, 2009;139–179.
3. Ohtani M, Kotaki H, Nishitateno K, et al. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997;281:428–433.
4. Curtin LI, Grakowsky JA, Suarez M, et al. Evaluation of buprenorphine in a postoperative pain model in rats. Comp Med 2009;59:60–71.
5. Schaap MWH, Uilenreef JJ, Mitsogiannis MD, et al. Optimizing the dosing interval of buprenorphine in rats. Lab Anim 2012;46:287–292.
6. Thompson AC, Kristal MB, Abdullah S, et al. Analgesic efficacy of orally administered buprenorphine in rats. Comp Med 2004;54:293–300.
7. Bourque SL, Adams MA, Nakatsu K, et al. Comparison of buprenorphine and meloxicam for postsurgical analgesia in rats: effects on body weight, locomotor activity, and hemodynamic parameters. J Am Assoc Lab Anim Sci 2010;49:617–622.
8. Cooper DM, Hoffman W, Wheat N, et al. Duration of effects on clinical parameters and referred hyperalgesia in rats after abdominal surgery and multiple doses of analgesia. Comp Med 2005;55:344–353.
9. Raffa RB, Porreca F, Cowan A, et al. Morphine receptor dissociation constant and the stimulus-effect relation for inhibition of gastrointestinal transit in the rat. Eur J Pharmacol 1982;79:11–16.
10. Sharma R, Manchanda SK, Nayar U. Role of opioid receptors in self-aggression in rats. Indian J Physiol Pharmacol 1991;35:165–169.
11. Walker EA, Young AM. Differential tolerance to antinociceptive effects of μ opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psycho-pharmacology (Berl) 2001;154:131–142.
12. Yassen A, Olofsen E, Kan J, et al. Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res 2008;25:183–193.
13. Yassen A, Olofsen E, Dahan A, et al. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats. J Pharmacol Exp Ther 2005;313:1136–1149.
14. US FDA. Simbadol buprenorphine injection. Freedom of Information summary. Original new animal drug application. NADA 141–434. Available at: www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM408852.pdf. Accessed Mar 3, 2017.
15. Johnson RA. Voluntary running-wheel activity, arterial blood gases, and thermal antinociception in rats after 3 buprenorphine formulations. J Am Assoc Lab Anim Sci 2016;55:306–311.
16. Wala EP, Holtman JR. Buprenorphine-induced hyperalgesia in the rat. Eur J Pharmacol 2011;651:89–95.
17. Cowan A. Buprenorphine and gastrointestinal transit in rats: effect of naloxone on the biphasic dose-response curve. Clin Exp Pharmacol Physiol 1992;19:47–49.
18. Clark JA Jr, Myers PH, Goelz MF, et al. Pica behavior associated with buprenorphine administration in the rat. Lab Anim Sci 1997;47:300–303.
19. Jacobson C. Adverse effects on growth rates in rats caused by buprenorphine administration. Lab Anim 2000;34:202–206.
20. De Jonghe BC, Lawler MP, Horn CC, et al. Pica as an adaptive response: kaolin consumption helps rats recover from chemotherapy-induced illness. Physiol Behav 2009;97:87–90.
21. Goineau S, Castagne V. Comparison of three preclinical models for nausea and vomiting assessment. J Pharmacol Toxicol Methods 2016;82:45–53.
22. Shi J. Evaluating the various phases of cisplatin-induced emesis in rats. Oncol Lett 2014;8:2017–2022.
23. Takeda N, Hasegawa S, Masahiro M, et al. Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav 1993;45:817–821.
24. Yamamoto K, Nakai M, Nohara K, et al. The anti-cancer drug-induced pica in rats is related to their clinical emetogenic potential. Eur J Pharmacol 2007;554:34–39.
25. Fog R. Behavioural effects in rats of morphine and amphetamine and a combination of the two drugs. Psychopharmacologia 1970;16:305–312.
26. Inbal R, Devor M, Tuchendler O, et al. Autonomy following nerve injury: genetic factors in the development of chronic pain. Pain 1980;9:327–337.
27. Mogilnicka E, Braestrup C. Noradrenergic influence on the stereotyped behaviour induced by amphetamine, phenethylamine and apomorphine. J Pharm Pharmacol 1976;28:253–255.
28. Mueller K, Saboda S, Palmour R, et al. Self-injurious behavior produced in rats by daily caffeine and continuous amphetamine. Pharmacol Biochem Behav 1982;17:613–617.
29. Pollock J, Kornetsky C. Evidence for the role of dopamine D1 receptors in morphine induced stereotypic behavior. Neurosci Lett 1989;102:291–296.
30. Institute for Laboratory Animal Research. Guide for the care and use of laboratory animals. 8th ed. Washington, DC: National Academics Press, 2011.
31. AVMA. AVMA guidelines for the euthanasia of animals: 2013 edition. Available at: www.avma.org/KB/Policies/Documents/euthanasia.pdf. Accessed Mar 3, 2017.
32. Creese I, Iversen S. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res 1973;55:369–382.
33. Aschoff J. Exogenous and endogenous components in circadian rhythms. Cold Spring Harb Symp Quant Biol 1960;25:11–28.
34. Siegel PS, Stuckey HL. The diurnal course of water and food intake in the normal mature rat. J Comp Physiol Psychol 1947;40:365–370.
35. Siegel PS. Food intake in the rat in relation to the dark-light cycle. J Comp Physiol Psychol 1961;54:294–301.
36. Terman M, Terman JS. Control of the rat's circadian self-stimulation rhythm by light-dark cycles. Physiol Behav 1975;14:781–789.
37. Zucker I. Light-dark rhythms in rat eating and drinking behavior. Physiol Behav 1971;6:115–126.
38. Hargreaves K, Dubner R, Brown F, et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77–88.
39. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001;53:597–652.
40. Meng X, Zhang Y, Lao L, et al. Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model. Pain 2013;154:294–305.
41. Zhang Y, Li A, Lao L, et al. Rostral ventromedial μ, but not κ, opioid receptors are involved in electroacupuncture anti-hyperalgesia in an inflammatory pain rat model. Brain Res 2011;1395:38–45.
42. Cheppudira BP. Characterization of hind paw licking and lifting to noxious radiant heat in the rat with and without chronic inflammation. J Neurosci Methods 2006;155:122–125.
43. Buerkle H, Yaksh T. Comparison of the spinal actions of the μ-opioid remifentanil with alfentanil and morphine in the rat. Anesthesiology 1996;84:94–102.
44. Endo D, Ikeda T, Ishida Y, et al. Effect of intrathecal administration of hemokinin-1 on the withdrawal response to noxious stimulation of the rat hind paw. Neurosci Lett 2006;392:114–117.
45. Knapp CM, Jha SH, Kornetsky C. Increased sensitization to morphine-induced oral stereotypy in aged rats. Pharmacol Biochem Behav 2004;79:491–497.
46. Mori T, Ito S, Kita T, et al. Effects of μ-, δ- and κ-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice. Eur J Pharmacol 2006;532:81–87.
47. Horner KA, Hebbard JC, Logan AS, et al. Activation of mu opioid receptors in the striatum differentially augments methamphetamine-induced gene expression and enhances stereotypic behavior. J Neurochem 2012;120:779–794.
Advertisement
OBJECTIVE To evaluate effects of high-concentration buprenorphine (HCB) on self-injurious behavior, food intake, fecal output, and thermal withdrawal latencies in healthy rats.
ANIMALS 8 Sprague-Dawley rats.
PROCEDURES Rats received 4 SC treatments (HCB at 0.075, 0.15, or 0.30 mg/kg [HCB0.075, HCB0.15, and HCB0.30, respectively] or 5% dextrose solution [0.20 mL/kg]) in a randomized, crossover-design study. Self-injurious behavior was assessed for 8 hours after injection. Food intake and fecal output were assessed for predetermined periods before and after treatment and separated into 12-hour light and dark periods for further analysis. Withdrawal latencies were assessed before (time 0) and at predetermined times after injection. Data were compared among treatments and time points.
RESULTS Self-injurious behavior was observed up to 8 hours after injection for all HCB, but not dextrose, treatments. Preinjection food intake and fecal output amounts were similar among groups and higher during the dark period than during the light period. Food intake after all HCB treatments was higher during the light period and lower during the dark period, compared with preinjection results for the same treatments and with postinjection results for dextrose administration. Light-period fecal output was lower after HCB0.15 and HCB0.30 administration, compared with preinjection values for the same treatments and postinjection values for dextrose administration. Percentage change in withdrawal latency was significantly higher than that at time 0 (ie, 0%) for only 1 treatment (HCB0.30) at 1 time point (1 hour after injection).
CONCLUSIONS AND CLINICAL RELEVANCE Although HCB0.30 produced a degree of thermal hypoalgesia in healthy rats, self-injurious behavior and alterations in food intake and fecal output were detected, potentially affecting clinical utility of the treatment.